EUVIMEDEUVIMED entdecken
Crossref

Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT

Qianhui Sun, Shengfang Wang, Ming Zeng iD, Minghao Liu, Chen Zhao iD, Boling Yi, Sining Hu iD, Bo Yu iD, Haibo Jia iD

Circulation: Cardiovascular Imaging · 2025

DOI: 10.1161/circimaging.124.017915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Cardiovascular Imaging, 2025. Verfasst von Qianhui Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang Province, China (Q.S., S.W., M.Z., M.L., C.Z., B.…. Hauptthemen laut MEDLINE: DNA Methyltransferase 3A, Plaque, Atherosclerotic, Mutation, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Clonal hematopoiesis of indeterminate potential is a novel, nontraditional risk factor linked to coronary heart disease. DNMT3A and TET2 are the 2 most prevalent clonal hematopoiesis of indeterminate potential-associated driver genes. This study aims to evaluate their effects on plaque characteristics and prognosis in patients with ST-segment–elevation myocardial infarction. METHODS: Consecutive patients with ST-segment–elevation myocardial infarction (May 2017–May 2019) undergoing routine optical coherence tomography were enrolled. Targeted deep exome sequencing of peripheral blood (custom panel targeting DNMT3A and TET2 ) identified mutations (with a threshold variant allele frequency ≥2%). The primary end point was major adverse cardiovascular events, defined as a composite end point that includes all-cause death, nonfatal myocardial infarction, nonfatal stroke, and revascularization due to clinical ischemic events. RESULTS: Among 628 patients, 12.3% were identified as carriers of DNMT3A or TET2 gene mutations. Patients with DNMT3A/TET2 mutations were older (62.5 versus 55.6 years; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Methyltransferase 3APlaque, AtheroscleroticMutationST Elevation Myocardial InfarctionTomography, Optical CoherenceDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesProto-Oncogene ProteinsCoronary Artery DiseaseHumansMaleFemaleMiddle AgedDioxygenasesPrognosisAgedRisk Factors

Stichwörter der Autor:innen

coronary diseasegene frequencyhumanslipidsstroke

Substanzen

DNA Methyltransferase 3ATET2 protein, humanDNMT3A protein, humanDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesProto-Oncogene Proteins

Autor:innen und Institutionen

  • Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang Province, China (Q.S., S.W., M.Z., M.L., C.Z., B. Yi, S.H., B. Yu, H.J.).
  • Key Laboratory of Myocardial Ischemia, Harbin Medical University, Heilongjiang Province, China (Q.S., S.W., M.Z., M.L., C.Z., B. Yi, S.H., B. Yu, H.J.).

ORCID-Profile: Ming Zeng, Chen Zhao, Sining Hu, Bo Yu, Haibo Jia

Zitieren

APA

Sun, Q., Wang, S., Zeng, M., Liu, M., Zhao, C., Yi, B., Hu, S., Yu, B., & Jia, H. (2025). Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.124.017915

Vancouver

Sun Q, Wang S, Zeng M, Liu M, Zhao C, Yi B, et al. Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT. Circulation: Cardiovascular Imaging. 2025. doi:10.1161/circimaging.124.017915

BibTeX
@article{Sun2025,
  author = {Sun, Qianhui and Wang, Shengfang and Zeng, Ming and Liu, Minghao and Zhao, Chen and Yi, Boling and Hu, Sining and Yu, Bo and Jia, Haibo},
  title = {Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2025},
  doi = {10.1161/circimaging.124.017915}
}
Kostenlos starten →